Overview
- The Department of Energy finalized an Other Transaction Agreement that allows work to begin on Oklo’s radioisotope-focused pilot under the agency’s Reactor Pilot Program.
- Oklo’s subsidiary Atomic Alchemy will lead the facility to produce isotopes for cancer care, scientific research, and national security uses.
- Atomic Alchemy withdrew its Nuclear Regulatory Commission construction permit application for the proposed Meitner-1 facility in Idaho to concentrate resources on the DOE-backed pilot.
- Oklo remains pre-revenue, reported Q3 EPS of -$0.20, and holds roughly $1.2 billion in cash as Wall Street coverage shows mixed ratings with a mean price target near $108.
- Shares were up about 3% to $98.76 on Wednesday as investors looked to a House Energy Subcommittee hearing as a potential policy catalyst alongside a new $2.7 billion uranium-enrichment initiative.